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PROFORMA 
Name    :  Ward No.   : 
Sex     :  Date of Admission : 
IP No.    : 
Serial No.    : 
Age     : 
Diabetes    : 
Hypertension   : 
Previous stroke / TIA  : 
Time after stroke onset  : 
Smoking    : 
Fasting Blood Sugar  : 
Blood pressure   : 
CT Brain    : 
Serum uric acid   : 
Outcome after 2 weeks of stroke: 
CONTROL CHART 
 
S. 
No. Name Age Sex 
BP 
mmHg 
FBS 
mg/dL 
Serum Uric 
Acid Level 
mg/dL 
Smoking 
1 M 36 F 120/80 106 3.7 - 
2 K 38 F 130/80 90 4.2 - 
3 P 35 F 120/80 96 4.8 - 
4 R 36 F 140/90 110 3.6 - 
5 S 38 F 120/80 110 3.2 - 
6 M 42 F 146/90 108 3.6 - 
7 R 48 F 150/100 130 3.4 - 
8 P 45 F 120/80 108 4.9 - 
9 L 46 F 130/80 96 4.8 - 
10 R 45 F 120/80 90 4.9 - 
11 M 52 F 130/80 94 3.1 - 
12 S 55 F 130/90 110 3.3 - 
13 R 56 F 146/90 129 3.6 - 
14 S 54 F 130/80 132 3.4 - 
15 P 58 F 130/90 110 3.5 - 
16 P 62 F 150/100 134 3.5 - 
17 R 65 F 130/90 116 3.3 - 
18 M 66 F 140/100 136 3.6 - 
19 N 68 F 130/80 110 3.3 - 
20 P 69 F 130/80 116 3.2 - 
1 P 34 M 120/80 90 4.8 - 
2 A 60 M 150/100 130 4.7 - 
3 M 55 M 140/90 110 4.4 + 
4 R 36 M 130/80 96 3.5 - 
5 B 32 M 120/80 106 3.4 - 
6 L 38 M 120/80 110 4.0 - 
7 M 40 M 146/90 120 3.9 + 
8 M 52 M 130/80 140 4.6 - 
9 K 58 M 120/80 110 4.8 - 
10 L 56 M 140/96 136 4.8 - 
11 P 55 M 130/80 110 4.2 + 
12 M 48 M 120/80 116 3.7 - 
13 P 42 M 130/80 106 4.2 - 
14 R 46 M 150/90 136 4.9 - 
15 L 42 M 120/80 90 4.2 - 
16 K 45 M 130/80 134 4.4 + 
17 M 64 M 130/90 110 4.2 - 
18 K 65 M 140/90 136 4.7 + 
19 P 65 M 120/80 110 5.3 - 
20 S 67 M 130/80 108 5.5 + 
 
 MASTER CHART 
S. 
No. Name Age Sex 
BP 
mm/Hg 
Time after 
onset of 
stroke 
FBS 
mg/dL 
Outcome 
scale 
Serum 
Uric Acid 
Level 
mg/dL 
Smoking 
1 V 35 M 140/100 40 120 1 4.2 + 
2 E 52 F 130/80 24 96 4 3.8  - 
3 D 54 M 150/100 4 138 4 3.2 + 
4 A 63 M 160/100 10 142 4 4.7  - 
5 V 70 M 130/90 12 160 2 3.9 + 
6 K 38 M 146/94 24 110 1 4.9 + 
7 M 55 F 136/84 20 90 4 4.0  - 
8 P 59 M 156/90 6 140 4 3.8 + 
9 A 62 M 150/96 12 136 4 5.0  - 
10 R 68 M 136/90 18 146 2 4.2 + 
11 S 60 M 154/90 20 112 3 4.1 + 
12 M 30 M 120/80 24 88 4 3.2  - 
13 S 34 M 150/100 38 130 5 3.5  - 
14 C 62 M 140/100 28 132 4 4.2  - 
15 J 70 M 130/90 30 126 3 3.2 + 
16 K 60 M 150/90 24 110 3 4.7 + 
17 M 30 M 130/80 12 80 4 3.8  - 
18 P 38 M 156/90 30 134 5 4.0  - 
19 A 64 M 146/100 12 138 4 4.8  - 
20 R 70 M 130/80 24 126 3 3.8 + 
21 N 55 M 130/90 20 122 4 4.5 + 
22 K 42 M 140/90 1 139 3 5.5 + 
23 S 70 M 140/100 22 123 4 4.3 + 
24 A 44 M 130/90 16 118 5 3.6 + 
25 P 40 M 120/84 4 129 4 4.2 + 
26 K 57 M 134/90 24 120 4 5.0 + 
27 M 46 M 150/90 3 140 3 5.8 + 
28 P 70 M 150/100 22 122 4 4.6 + 
29 R 48 M 130/90 18 106 5 4.2 + 
30 S 40 M 126/84 6 131 4 5.0 + 
S. 
No. Name Age Sex 
BP 
mm/Hg 
Time after 
onset of 
stroke 
FBS 
mg/dL 
Outcome 
scale 
Serum 
Uric Acid 
Level 
mg/dL 
Smoking 
31 S 70 M 160/100 18 111 4 3.8 + 
32 M 69 M 150/90 3 132 3 5.7 + 
33 P 47 M 160/90 20 108 5 4.2 + 
34 A 70 M 150/100 28 98 4 4.6  - 
35 A 60 F 130/90 32 106 4 4.6  - 
36 K 70 M 150/90 20 106 4 4.0 + 
37 P 68 M 156/90 13 138 3 6.0 + 
38 M 44 M 160/94 12 110 5 4.7 + 
39 R 70 M 160/100 20 96 4 5.0  - 
40 L 60 F 130/80 28 110 4 5.0  - 
41 B 51 F 120/80 38 110 4 4.8  - 
42 B 55 F 130/90 29 124 3 5.1  - 
43 M 65 F 150/90 2 108 4 4.1  - 
44 D 50 F 160/90 18 120 4 3.8  - 
45 L 58 F 130/80 29 126 4 3.2  - 
46 K 54 F 120/80 30 106 4 5.0  - 
47 M 58 F 126/86 24 120 3 5.4  - 
48 P 62 F 160/94 10 112 4 4.0  - 
49 N 50 F 150/100 12 107 4 3.2  - 
50 R 54 F 130/90 26 116 4 3.6  - 
51 M 52 F 120/80 29 120 4 3.2  - 
52 L 61 F 140/100 37 128 4 5.4  - 
53 P 56 F 130/80 24 110 4 3.6  - 
54 R 64 F 150/100 20 130 4 5.0  - 
55 R 58 F 140/90 40 112 4 6.1  - 
56 G 57 M 160/90 7 120 2 7.2 + 
57 R 60 M 146/100 19 110 3 7.3 + 
58 K 54 F 150/90 20 108 4 6.4  - 
59 P 58 M 160/100 10 115 2 7.6 + 
60 K 60 M 150/90 14 106 3 7.8 + 
61 S 50 M 130/90 11 106 4 7.2 + 
62 S 60 M 120/80 23 124 4 7.0 + 
63 B 32 M 120/80 29 108 4 7.0 + 
S. 
No. Name Age Sex 
BP 
mm/Hg 
Time after 
onset of 
stroke 
FBS 
mg/dL 
Outcome 
scale 
Serum 
Uric Acid 
Level 
mg/dL 
Smoking 
64 A 57 M 130/94 40 162 3 7.7  - 
65 B 60 M 140/90 15 158 3 7.4  - 
66 K 50 M 134/80 20 110 4 7.3 + 
67 M 60 M 126/80 24 120 4 7.0 + 
68 S 36 M 120/80 26 110 4 7.1 + 
69 N 54 M 130/80 40 140 3 7.4  - 
70 P 60 M 146/90 20 146 3 7.8  - 
71 P 58 M 140/90 18 96 3 7.4 + 
72 K 50 M 130/90 2 90 4 7.8  - 
73 K 70 M 140/100 18 118 3 7.1 + 
74 A 54 M 130/90 8 98 2 7.6 + 
75 N 60 M 146/90 13 102 4 7.9 + 
76 B 54 M 150/100 10 90 3 7.8 + 
77 A 50 M 130/90 12 94 4 7.0  - 
78 P 70 M 146/100 20 110 3 7.8 + 
79 R 58 M 130/90 20 90 2 7.5 + 
80 L 60 M 150/100 12 110 4 7.1 + 
81 N 70 M 150/90 2 129 3 7.6  - 
82 K 65 F 140/100 15 151 2 8.0  - 
83 S 52 F 134/90 6 140 3 7.8  - 
84 S 65 F 140/90 11 126 4 6.4  - 
85 SK 53 F 120/80 29 122 3 6.7  - 
86 P 70 M 160/100 6 130 3 7.8  - 
87 B 67 F 150/90 12 146 2 7.1  - 
88 L 56 F 130/80 20 136 3 6.4  - 
89 R 68 F 150/100 10 128 4 5.9  - 
90 M 56 F 120/80 30 110 3 6.9  - 
91 P 58 F 130/80 33 116 2 6.0  - 
92 G 54 F 120/80 16 120 3 7.2  - 
93 A 62 F 130/80 37 122 2 6.9  - 
94 A 68 F 150/100 21 101 4 7.0  - 
95 S 50 M 130/90 36 100 4 7.4  - 
96 S 52 M 150/100 16 96 4 7.2  - 
S. 
No. Name Age Sex 
BP 
mm/Hg 
Time after 
onset of 
stroke 
FBS 
mg/dL 
Outcome 
scale 
Serum 
Uric Acid 
Level 
mg/dL 
Smoking 
97 R 56 F 136/90 34 116 2 6.0  - 
98 L 52 F 126/80 24 110 3 6.2  - 
99 M 66 F 130/80 30 120 2 6.8  - 
100 K 64 F 150/100 20 110 4 6.4  - 
101 R 50 M 130/80 40 106 4 7.1  - 
102 R 56 M 156/100 18 90 4 7.4  - 
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INTRODUCTION 
In clinical practice, uric acid has been used as a marker of 
severe metabolic disturbances.  Its antioxidant property has not 
been considered much for a longtime. 
The plasma concentration of uric acid is almost 10-fold higher 
than other antioxidants such as Vitamin C and Vitamin E.  It is 
considered that uric acid has much higher antioxidant capacity1.  
Uric acid which is formed by catabolism of purine is proposed to 
neutralize the free radical injury that occurs in ischemic stroke. 
Epidemiological studies have suggested a direct relationship 
between the levels of the natural antioxidant uric acid and the risk 
of cerebrovascular and coronary ischemic events2.  However it is 
not completely clear whether this association indicates that uric 
acid is an independent ischemic risk factor or it represents a 
marker of atherosclerotic disease.  Whether the concentration of 
uric acid at the onset of ischemic symptoms influences the severity 
of stroke also remains to be elucidated. 
 2
 
AIM OF THE STUDY 
1. To estimate the level of serum uric acid in patients with 
acute ischemic stroke   
2. To findout whether there is variation related to gender 
and age.  
3. To identify whether uric acid level among the stroke cases 
has any association with diabetes and hypertension. 
4. To study its significance in the outcome of these patients. 
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REVIEW OF LITERATURE 
Stroke or cerebrovascular accident by definition of WHO is a 
rapidly developing clinical symptoms and/or signs of focal 
neurological deficit and at times global loss of cerebral function 
(coma) lasting longer than 24 hrs or leading to death with no 
apparent cause other than vascular origin3. 
The 24 hours threshold in the definition excludes transient 
ischemic attacks (TIA). 
Stroke includes a number of syndromes with differing 
etiologies, epidemiology, prognosis and treatment.  These are listed 
in the WHO’s international classification of diseases (ICD – 9th 
revision). 
a. Sub arachnoid haemorrhage  
b. Cerebral haemorrhage  
c. Cerebral thrombosis or embolism  
d. Occlusion of precerebral arteries 
e. Transient cerebral ischemia of more than 24 hours 
f. III defined cerebrovascular disease (i.e., underlying pathology 
in brain is not determined. 
Stroke is a world wide health problem making an important 
contribution to morbidity, mortality and disability in developed as 
well as in developing countries. 
 4
Stroke is of 2 types, ischemic and hemorrhagic . 83% of stroke 
is due to ischemia, while hemorrhagic stroke is only 17%4 (Fig. 1).  
Cerebral thrombosis is usually the most frequent form (about 
50%) of stroke encountered in clinical studies, though there are 
substantial differences in frequency from place to place.  Cerebral 
embolism comes next forming 32% of stroke. 
Cerebral ischemia is caused by a reduction in blood flow that 
lasts for a several seconds to few minutes.  Neurologic symptoms 
manifest within 10 sec. because neurons lack glycogen and suffer 
rapid energy failure.  This cerebral ischemia or infarction is usually 
caused by thrombosis of the cerebral vessels themselves or by 
emboli from a proximal arterial source or the heart. 
Fig.1 :  Types of cerebrovascular accident  
Large  vessel 
thrombotic 
31%
Small vessel 
thrombotic 
20%
Embolic
32%
Sub arachnoid 
haemorrage
7%
Intracerebral 
haemorrage
10%
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The causes of ischemia-infarction are: 
Ischemic Stroke  (83% of stroke) 
a.  Thrombotic 51% 
It consists of 2 sub categories : 
(i) Large vessel thrombosis - 31% 
 (e.g. carotid, middle cerebral, basilar arteries) 
(ii) Small vessel thrombosis - 20%  
(Lacunar stroke) 
 (e.g.  lenticulostriate, basilar penetrating, medullary) 
b.  Embolic – 32% 
PATHOPHYSIOLOGY OF CEREBRAL ISCHEMIA 
The brain is an obligatory aerobe.  It derives its energy from 
the oxidative metabolism of glucose.  There are only negligible 
stores of glucose in the brain.  So when the cerebral blood flow falls 
and the brain becomes ischemic a series of functional and 
neurophysiological changes, which are dependant on the oxidative 
metabolism of glucose to provide energy in the form of ATP occurs 
at various thresholds of flow5. 
The normal cerebral blood flow (CBF) in man is 50ml/100 
gms of brain/min.  Using positron Emission Tomography, the 
cerebral energy metabolism is measured as cerebral metabolic rate 
of oxygen (CMRO2) and of glucose (CMR glu).  It has also studied 
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that the oxygen extraction fraction (OEF) remains the same 
throughout the brain6.  Therefore in resting normal human brain, 
the CBF is a reliable reflection of CMRO2. 
In ischemia when CBF falls below about 20 ml/100 gm/min6, 
the oxygen extraction fraction becomes maximal and the CMRO2 
begins to fall.  Infact a high OEF is only seen early after acute 
ischemic stroke, in the first day or so. 
If flow is restored, functional recovery is still possible.  At this 
stage, lactate production increases due to ineffective anaerobic 
metabolism of glucose.  The pH falls and ATP synthesis is 
impaired.  As flow falls further, energy – dependent functions of the 
cell membranes becomes progressively affected.  Water, sodium and 
chloride enters the cells.  Calcium also enters and Potassium (k+) 
leaks out7.  Cellular transport mechanisms and neurotransmitter 
systems fail. Certain potentially neurotoxic transmitters are 
released such as L-glutamate.  The oxygen radicals and lipid 
peroxides are formed which damage the cell further8.  Neurons 
start releasing PAF, (Platelet Activating Factor) which may be 
neurotoxic. 
When the blood flow falls further less than 10ml/100gm/min, 
infarction occurs and even if flow is restored function does not 
recover.  At this stage, the CMRO2 and CBF is low and OEF may be 
low indicating the CBF is in excess of requirements for the low 
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metabolic demands of the infracted tissue.  It is called luxury 
perfusion9.  In absolute luxury perfusion, CBF is increased which is 
termed as hyperperfusion. 
The consequences of the fall in CBF depend not just on the 
depth of ischemia, but also on its duration.  In focal ischemia, flow 
is almost never reduced to zero because of the collateral blood 
supply which is therefore, a further factor in determining the 
metabolic consequences.  The local CBF may also be influenced by 
the development of cerebral edema and raised intracranial 
pressure.  Acid metabolites and the increasing extracellular 
potassium concentrations cause vasodilatation.  Vasoconstrictor 
prostaglandins are released from aggregating platelets and 
damaged cell membranes. 
Blood viscosity and aggregation of formed elements slow the 
microcirculation and eventually thrombosis.  The metabolic 
consequences of ischemia may be exacerbated in the presence of 
high prevailing glucose concentration.  But the worst outcome may 
be related to the hyperglycaemia of stress response and reflect the 
severity of initial stroke10.  When the lactate levels are increased, 
seizures may occur. 
Systemic hypoxia (as a consequence of pneumonia etc) and 
dehydration, increasing the hematocrit and blood viscosity are 
further exacerbating factors. 
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Damaged brain may also have impaired responses to PaCO2 
and PaO2 as well as impaired autoregulation and perfusion reserve.  
This makes the brain very sensitive to any further insults such as 
systemic hypoxia, hypotension and raised intracranial pressure. 
Free Radical damage 
Ischemia induced free radical damage is most likely to occur 
if ischemia is followed by recirculation.  This occurs because oxygen 
radicals are formed when reduced compound which is accumulated 
during ischemia is reoxidised.  However free radical production can 
occur at relatively low oxygen tension and can be triggered by the 
accumulation of reduced compounds. 
Ischemia promotes the conversion of Xanthine 
Dehydrogenase (XDH) to Xanthine Oxidase (XO).  A rise in calcium 
may activate proteases which favours this conversion.  Whereas 
XDH activity does not produce reactive oxygen species, the XO 
reaction is a major source of free radicals during ischemia 
reperfusion injury. 
Hypoxanthine +O2 → Xanthine +O2 - + H2 O2 
Xanthine + O2 → Uric acid + O2- + H2 O2 
Another source of free radicals is Nitric Oxide.  O2 and No 
decompose to form toxic peroxynitrate ion (NO3-). No synthetase is 
also stimulated by the rising calcium levels in the ischemic tissue. 
 9
Uric acid, its mono-anion urate (at physiological pH values) is 
traditionally considered to be a metabolic inert end product of 
purine metabolism in man without any physiological value. 
Uric acid is implicated in various pathological conditions such 
as Gout, Lesch-Nyhan syndrome, Xanthinuria etc.  However, this 
ubiquituous compound has proven to be a selective anti oxidant11, 
capable especially of reaction with hydroxyl radicals and 
hypochlorous acid.  It also gets converted to innocuous products 
(allantoin, allantoate, glyoxalate, urea, oxalate).  There is now 
evidence for such processes not only in vitro in isolated organs but 
also in human lung in vivo.  Urate may also serve as an oxidizable 
co-substrate for the enzyme cyclooxygenase. The major site of urate 
production as shown for coronary system is the mircovascular 
endothelium in isolated organ preparations.  Urate is shown to 
protect against reperfusion damage induced by activated 
granulocytes and cells known to produce a variety of radicals and 
oxidants.  Intriguingly, urate prevent oxidative inactivation of 
endothelial enzymes (cyclooxygenase, Angiotensin Converting 
Enzymes) preserves the ability of the endothelium to mediate 
vascular dilatation in the face of the oxidative stress.  This suggests 
a particular relationship between the site of urate formation and 
the need for a biologically potent free radical scavenger and 
autoooxidant. 
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Risk factors for cerebral infarction 
1. Unmodifiable risk factors 
2. Major modifiable risk factors  
3. Questionable rare or weak modifiable risk factors. 
4. Risk factors predominant in the young. 
Risk factors for cerebral infarction 
Unmodifiable risk  
factors 
Questionable, rare, or 
weak modifiable risk 
factors 
Risk factors  
predominant in the young 
Age 
 
Sex 
 
Race 
 
Family history 
Previous stroke 
-------------------------------------
Major modifiable 
Risk factors 
 
Atrial fibrillation 
Hypertension 
 
Isolated systolic 
hypertension 
 
Myocardial infarction 
Other heart disease 
Diabetes mellitus  
 
Transient ischemic 
attacks 
Smoking 
AIDS 
 
Alcohol 
 
 
Fibrinogen and  
platelets 
Lipids 
Exercise 
Hematocrit 
 
Water supply 
Anticardiolipin 
antibodies 
 
Oral contraceptive 
 
Pregnancy 
Homocystinuria 
Diet 
Socioeconomic status 
 
Season 
Claudication 
Mitral valve leaflet 
prolapse 
Sickle cell disease and 
other hemoglobinopathies. 
Migraine 
 
Cocaine abuse 
Obstructive sleep apnea 
Intercurrent infection 
 
Patent foramen ovale 
Atrial septal aneurysm 
 
System Lupus 
erythematosus 
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A. Unmodifiable Risk factors 
a. Age 
 Age is the single most powerful risk factor for cerebral 
infarction.  Since the increase with age is exponential, doubling or 
tripling with every decade after the fifth12. 
b. Sex 
 Mortality rates for men are 23% to 115% higher than for 
women in all countries13. 
c. Race 
 There is generally a higher incidence of all strokes types and 
cerebral infarction in blacks14. 
d. Previous stroke 
 The recurrence rate of cerebral infarction is 10-30%.  The 
first 6 months is the period of highest risk15.  Hypertension, 
Diabetes and Smoking increase the risk, while an infarction of 
undetermined cause is associated with a diminished risk. 
2. Modifiable risk factors 
a. Atrial Fibrillation 
 Atrial fibrillation causes 20% of all infarcts and is associated 
with a relative risk of death from stroke of 12.2516.  Silent infarcts 
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are found in 20% more of the population with atrial fibrillation and 
this is exacerbated by increasing age and left atrial diameter. 
b.  Hypertension 
After age, hypertension is the most powerful risk factor for 
cerebral infarction.  Both systolic and diastolic pressures are 
important.  Sex differences are not prominent in analyses of the 
effects of hypertension on stroke.  Prolonged treatment of diastolic 
BP to produce a fall of 6 mmHg decreases the stroke risk by 40% 
and the benefits accrue within 3 years17. 
c.  Myocardial infarction 
Cerebral infarction occurs in between 1 % and 1.25% of cases 
within 1 year after myocardial infarction18.  Transmural infarcts 
pose a greater risk than subendocardial infarcts.  A history of 
myocardial infarction is also a risk factor for cerebral infarction. 
d.  Other Heart disease 
Cardiac disease in general doubles the risk of stroke.  While 
left ventricular hypertrophy quadruples it, independent of 
hypertension.  Cardiac failure, coronary Heart disease and angina 
increases the risk of cerebral infarction. 
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e.  Diabetes Mellitus 
Though variable, the evidence now supports diabetes as a 
risk factor for stroke19.  Impaired glucose tolerance may be a risk 
factor and an elevated glycosylated hemoglobin may be found in 
upto 42% patients with cerebral infarcts not previously known to 
have diabetes.  
f.  Transient  ischemic Attacks 
The incidence of stroke increases after TIA.  The relative risk 
of stroke after TIA is 13.4 in the first 12 months and 7 over first 7 
years20. 
g.  Smoking 
Smoking is one of the most important risk factors.  There is a 
dose response relationship, the risk doubling in the heaviest of 
smokers18.  In the Framingham study, cessation of smoking 
removed the additional risk of stroke within 2 years. 
h.  Alcohol 
The effect of alcohol on cerebral infarction has two aspects.  
These being sudden heavy (binge) drinking and chronic 
consumption.  There is evidence for an association between sudden 
heavy drinking and the onset of cerebral infarction in young 
adults21.  Chronic light alcohol intake is associated with a 
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decreased risk of stroke.  Chronic heavy consumption 180 – 400 
g/wk is associated with an increased risk. 
i.  Lipids 
Total cholesterol has a weak association with cerebral 
infarction.  Framingham study suggest a weak correlation between 
cholesterol and triglycerides and the risk of atherothrombotic brain 
infarction. 
j.  Exercise 
Lack of exercise may increase the risk of all stroke in 
women22. 
Minor factors 
Soft water has been associated with an increased risk (7%) of 
death from stroke according to death certificates. 
Anti CardioLipin antibodies are associated with increased 
risk for cerebral infarction. 
Homocystinuria is a recognized high risk factor for stroke. 
Acquired Immuno Deficiency Syndrome (AIDS) is a risk 
factor for infarction.  The precise mechanism is unknown, but an 
associated CNS infection typically with Cryptococcus species, 
tuberculosis or varicella Zoster is implicated in half of the cases. 
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Pathophysiology of ischemic stroke subtypes 
Cerebral infarction is not a single disease and the 
differentiation of several clinical, pathophysiologic and etiologic 
subtypes may be critical for adequate management of patients. 
The most common mechanisms of ischemic stroke is 
thrombosis and embolic, either from an atheromatous arterial 
lesion (artery to artery thromboembolism) or from the heart (cardio 
embolism).  Less commonly, in situ occlusion of an extra cranial or 
a cerebral artery may be incriminated in the absence of embolism. 
• First, when the occluded artery is a small perforating branch 
without collateral supply i.e (lacunar infarct.)23  
• Second, when large-artery occlusion may produce 
hemodynamic failure in the corresponding territory because 
of lack of functioning anastomoses (Hemodynamic infarction). 
• Finally, abnormalities of the blood, itself may lead to 
ischemic stroke [(eg) coagulation disorders, hypervisocity, 
anaemia, leukemia and related disorders]. 
Intracranial atherosclerosis play a major role in Asians and 
to a lesser extent in blacks.  In whites, extracranial atherosclerosis 
causes artery to artery embolism.  However this distinction is valid 
mainly for anterior circulation.  While recent studies have shown 
that intracranial vertebral artery or basilar artery atherosclerosis 
is also an important cause of posterior circulation infarcts24.  
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MIDDLE CEREBRAL ARTERY – SUPERFICIAL TERRITORY  
INFARCTS 
Superficial branches of the middle cerebral artery (MCA) 
originate distal to the origin of lenticulostriate arteries.  As they 
course in the subarachnoid space, they are called pial branches.  
They supply the cortical, subcortical territory of the MCA after the 
MCA trunk divide in to two (upper and lower) or three (Upper, 
middle and lower) divisions which in their turn divide into several 
branches. 
MCA pial territory infarcts may be partial when only a distal 
branch is occluded, or they may be rather large when the occlusion 
is more proximal at the level of the MCA bifurcation or trifurcation 
and the collateral system is not adequate.  Because one 
characteristic of the pial artery network is to have extensive 
anastomoses, multiple distal emboli are necessary. 
The presumed cause of embolism is large-artery disease 
(>50%) internal carotid artery (ICA) or MCA stenosis or occlusion 
in one third of the patients and cardiac disease in one quarter of 
the patients.  Interestingly, potential cardiac sources of embolism 
are particularly common with infarcts in the territory of the lower 
division of the MCA which are also associated with more disability 
than infarcts in the territory of the upper division. 
 18
Because most of the frontal, temporal and parietal lobes are 
supplied by the MCA pial branches, the neurologic picture may be 
variable according to the location of the infarct. 
INFARCTS IN THE TERRITORY OF THE DEEP PERFORATORS 
FROM THE CAROTID SYSTEM 
In contrast to the pial artery network, the deep perforators 
from the distal ICA or the MCA trunk are terminal branches that 
perforate the basal part of the cerebral hemispheres.  For that 
reason, occlusion of one or several perforators is always associated 
with an infarcts usually small in the corresponding territory.  
These small deep infarcts are often called ‘Lacunar’, but it should 
be remembered that lacunar may be caused by non ischemic 
processes such as small hemorrhage or non ischemic dilatation of 
periarteriolar space. 
It is widely accepted that lacunar infarcts are usually due to 
in situ occlusion of the corresponding small perforator by a micro 
atheromatous or lipohyalinotic process associated with chronic 
arterial hypertension.  This assumption appears correct for very 
small lacunar infarcts (<0.3 – 0.5cm) associated with occlusion of 
one single perforator but these infarcts are usually asymptomatic.  
Although small artery disease probably remains a leading etiology, 
in larger (0.5 – 1.5 cm or larger) and symptomatic small deep 
infarcts, other potential causes may also be considered, since more 
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than one third of these patients may have a potential cardiac 
source of embolism or large artery disease (>50%) ICA stenosis or 
occlusion, often in the absence of concomitant hypertension. 
Embolism to the MCA trunk is a particularly common cause 
of complete lenticulostriate territory infarction (known as large 
striate capsular infarcts or extended infarcts of the lentiform 
nucleus), by occluding the leticulostriate arteries at their origin 
while collateral circulation explains sparing of the superficial pial 
territory. 
Clinical manifestations are largely dependent on the size of 
infarct.  The larger infarcts may produce dysfunction not markedly 
different from superficial MCA territory infarcts.  Smaller infarcts 
have often been linked to isolated contralateral motor or sensory 
disturbances (lacunar syndromes). 
The classic lacunar syndrome are: 
1. Pure motor hemiparesis from an infarct in the posterior limb 
of the internal capsule or basis pontis, the face arm and leg 
are almost always involved. 
2. Pure sensory stroke – from an infarct in the ventro lateral 
thalamus. 
3. Ataxic hemiparesis – from an infarct in the base of the pontis. 
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4. Dysarthria and a clumsy hand or arm due to infarction in the 
base of the pons or in the genu of the internal capsule. 
5. Pure motor hemiparesis with motor or Brocas aphasia due to 
thrombotic occlusion of a lenticulostriate branch supplying 
the genu and anterior limb of the internal capsule and 
adjacent white matter of the corona radiata. 
ANTERIOR CEREBRAL ARTERY INFARCTS 
Although the ACA originates from the carotid system at the 
same level as the MCA, ACA territory infarcts are between 20-30 
times less common than MCA territory infarcts25.  However, 
etiologic patterns do not differ between MCA territory infarcts. 
Infarcts in the territory of Heubner’s artery or in the territory 
of the anterior striate branches are usually discussed together with 
lenticulostriate infarcts in general. 
In ACA, pial territory infarcts, the association of crural 
hemiparesis, mutism at onset, transcortical motor aphasia, frontal 
tasks impairment, mood disturbance, incontinence, grasp reflex 
and unilateral left apraxia may help to localize the infarct before 
Computed Tomography or magnetic resonance Imaging, but 
proportional (arm-leg-arm) hemiparesis or hemisensory defect, 
hemineglect or confessional state may be misleading.  
Simultaneous bilateral ACA territory infarction may occur in 
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relation to a common origin of both ACA territory infarction may 
occur in relation to a common origin of both ACAs.  Akinetic 
mutism with incontinence and bilateral grasp reflex is suggestive of 
this type of infarct, which is uncommon (<10%). 
BORDER ZONE CEREBRAL INFARCTS 
Infarction may develop at the level of the collateral border 
zone between two main pial arterial territories.  Those extra 
territorial infarcts are commonly called watershed or distal field 
infarcts.  They usually occur between the ACA and MCA territories 
anterior water shed infarcts or between the MCA and posterior 
cerebral artery (PCA) territories – posterior water shed infarcts. 
In anterior water shed infarcts, hemiparesis, predominating 
in the lower limb, with transcortical motor aphasia when lesion is 
on the left, is the most common neurologic finding when the infarct 
predominates in the subcortical white matter, mimicking ACA 
territory infarction.  However, when the infarct is limited to the 
cortex, proximal brachial hemiparesis is present because junction of 
the arm-shoulder representation on the motor strip, thus in 
bilateral anterior watershed cortical infarcts, a picture bi-brachial 
paralysis (man-in-the -barrel) may occur. 
Posterior watershed infarcts yield a neurologic picture that is 
similar to that of posterior MCA pial territory infarcts except for a 
more common occurrence of transcortical sensory aphasia. 
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Bilateral watershed infarcts often have a symmetrical 
pattern.  They usually develop in relation to episodes of severe 
hypotension, cardio circulatory distress, prolonged hypoxemeia or 
bilateral severe carotid disease26.  Venterolateral watershed 
infarcts are also associated with some degree of hemodynamic 
failure (hypotension, bradycardia, high hematocrit level) in 
patients with ipsilateral carotid occlusion or tight stenoses.  They 
are good examples of hemodynamic infarcts, though mircroemboli 
may account for some border zone infarcts. 
An infarction between the deep and superficial (pial) 
territories of the MCA is uncommon.  It is called a sub cortical 
watershed26. Hemiparesis with or without hemisensory disturbance 
is the most common neurologic disturbance in these infarcts. 
POSTERIOR CEREBRAL ARTERY - SUPERFICIAL TERRITORY 
INFARCTS 
The superficial (pial) branches of the PCA include the 
hippocampal, medial temporo – occipital, splenial, internal occipital 
and calcarine branches.  The posterior choroidal branches have an 
internal temporal pial network, but they are usually considered 
with the deep branches of the thalamus.  Infarcts limited to the 
territory of just one branch of the PCA are the most commonest 
type of PCA pial territory infarction (uniterritorial), often involving 
the calcarine artery territory.  Isolated mediotemporal involvement 
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is rare.  The most common biterritorial infarct combines calcarine 
and internal occipital arteries territory involvement. 
The neurologic manifestation are dominated by visual 
symptoms, which may be simple (hemianopia) or complex (alexia, 
achromatopsia, agnosia, visual memory impairment.) 
In pathologic series, PCA infarction is often due to 
compression by edema during temporal lobe herniation.  In a 
clinical setting the etiology is usually embolic, mainly from the 
heart, vertebro basilar atherosclerosis. 
THALAMIC INFARCTS 
The arterial supply to thalamus may be divided into four 
main groups. 
1. The paramedian or thalomo perforate branches from the P1 
segment of the PCA.   
2. The infero lateral or thalamo geniculate branches from the P2  
segment of the PCA.  
3. The posterior choroidal arteries (one lateral and one medial 
group) from the P2 segment of PCA.   
4. The tuberothalamic or polar branches originate from 
posterior communication artery.  
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The etiology of thalamic infarct is varied.  Small vessel 
disease associated with hypertension or diabetes accounts for not 
more than one third of the cases, while cardio embolism and artery 
– to – artery embolism accounts for atleast 25% to 30%.  Other 
causes such as arteritis, migraine and so on may also be 
responsible.  Usually simultaneous occlusion of several perforators 
(from embolism) may be necessary to lead to infarct. 
BRAIN STEM INFARCTS 
Mid brain, pontine and medullary infarcts usually develop in 
characteristic territories in relation to a stereotyped blood supply 
system which includes (from medial to lateral side) paramedian 
perforating branches and short circumferential arteries directly 
from the basilar artery and large circumferential arteries, which 
are infact the three cerebellar arteries: 
1. The Superior Cerebellar Artery (SCA) 
2. Anterior Inferior Cerebellar Artery (AICA) and 
3. Posterior Inferior Cerebellar Artery (PICA) and supply the 
dorsal brain stem as well as their cerebellar territory 
Most of the clinically relevant brain stem infarcts involve the 
paramedian and lateral (short circumferential branches) 
territories.  Thus, they may be associated with small – vessel 
disease (lacunar infarction) but also with basilar artery (for the 
pons and mid brain) or vertebral artery (for the medulla) disease 
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that obstructs the mouth of these small arteries (branch disease).  
Large embolism, which may stop more proximally in the basilar 
artery, lead to large infarcts not limited to the brain stem.  The 
neurologic manipulations caused by brain stem infarcts are 
multiple. 
CEREBELLAR INFARCTS 
1.  PICA Territory Infarcts 
 PICA territory infarcts are the most common type of 
symptomatic cerebellar infarcts.  Most cases seem related to 
atheromatous occlusion of the vertebral artery, less commonly the 
PICA itself. 
2.  AICA Territory Infarcts 
 AICA territory infarcts are the less common type of cerebellar 
infarcts.  Infarcts in the lateral part of the lower pons is usual in 
association with cerebellar involvement.  Contrary to PICA and 
SCA territory infarcts, cardioembolism seems to be an uncommon 
cause.  Atherosclerosis plays a major role. 
3. SCA Territory Infarcts 
In SCA territory infarcts, clinically relevant brain stem (Mid 
brain) involvement is less common than in AICA territory infarcts, 
where cardio embolism is a classic cause. 
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Other Cerebellar Infarcts 
Large cerebellar infarcts are usually MCA territory infarcts 
in patients with AICA aplasia.  They are typically responsible for a 
rapid deterioration, tonsillar herniation and death in the absence of 
surgical intervention. 
Watershed cerebellar infarcts may occur at the border zone 
between PICA, SCA and AICA territories.  Their clinical diagnosis 
is controversial since the overlap of the cerebellar arteries may be 
particularly variable. 
INVESTIGATIONS  
COMPUTED TOMOGRAPHY (CT) 
The role of computed Tomography in the diagnosis of cerebral 
infarction is well established.  CT can distinguish between an 
ischemic bland-non haemorrhagic stroke, haemorrhagic infarction 
and primary intracerebral Haemorrhage27. 
In the clinical setting of a transient ischemic attacks (TIA) 
the CT scan is usually normal, however the detection of white 
matter or capsular hypodensity  (chronic ischemic change) 
establishes the presence of underlying vascular disease. 
The classic neuropathologic process that occur during the 
evolution of an infarction is well reflected by the CT scan.  The 
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radiologic imaging characteristics are divided in to four stages and 
are dependant on the time from the onset of ictus.  These stages are 
divided into 
1. Hyperacute  less than 24 hrs 
2. Acute   24 hrs – 7 days 
3. Subacute   8-21 days 
4. Chronic  More than 21 days 
MAGNETIC RESONANCE IMAGING (MRI) 
Image contrast with magnetic resonance imaging is 
dependent on three tissue variables.  T1 – Relaxation time, T2 – 
Relaxation time and Proton density. 
Ischemia one hour after the event can be detected by MR 
imaging.  MRI reliably documents the extent and location of 
infarction in all area of the brain, including the posterior fossa and 
cortical surface.  Diffusion weighted imaging is more sensitive for 
early brain infarction.  Magnetic Resonance angiography is highly 
sensitive for extracranial internal carotid plaque as well as 
intracranial stenosis of large vessels.  MRI proves superior 
information compared with CT in nearly every case of stroke. 
CEREBRAL ANGIOGRAPHY 
Conventional X-Ray cerebral angiography is the “gold 
standard” for identifying and quantifying atherosclerotic stenoses 
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of the cerebral arteries and other pathologies.  Recent studies have 
documented that intra arterial delivery of thrombolytic agents to 
patients with acute MCA infarct can effectively recanalize vessels 
and improve clinical outcomes. 
Baseline tests for most ischemic stroke patients 
Sl. 
No 
Investigation Treatable disorders detected 
1. Full blood count Anaemia, Polycythaemia, 
leukemia, thrombocytopenia 
2. ESR Vasculitis, infective endocarditis 
hyperviscosity 
3. Plasma glucose Diabetes, hypoglycaemia 
4. Plasma cholesterol Hyper cholesterolemia 
5. Syphilis serology Syphilis, anti cardiolipin antibody 
6. Urine analysis Diabetes, renal disease 
7. Electro Cardiogram LVH, arrhythmias, conduction 
block, myocardial ischemia or 
infarction 
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PREDICTION OF STROKE OUTCOME 
The outcome of stroke is influenced by many factors.  Among 
them, some of the most important are demographic factors such as 
age, sex, etc, risk factors, clinical examination findings, laboratory 
tests and imaging. These factors provide important insight 
regarding outcome. 
1.  DEMOGRAPHIC FACTORS 
a.  Age 
It is one of the major factors which can negatively influence 
the outcome.  Poor outcome in old age is due to increased frequency 
of secondary complications such as pneumonia, bed sores etc. 
b.  Gender 
Stroke in males poses poor outcome. Endogenous estrogens in 
females is found to be neuroprotective and has flow preserving 
effects. 
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2.  RISK FACTORS 
Previous stroke and atrial fibrillation causes more disability 
and associated with increased mortality16. 
3.  CLINICAL FINDING 
a.  Level of Consciousness and Gaze Deviation 
A decrease in the level of consciousness and presence of gaze 
deviation indicates poor outcome. 
b.  Blood Pressure 
Systemic hypotension can cause a fall in cerebral blood flow 
which may cause a decreased blood flow to the infracted area. 
A rise in BP may have long term adverse effects on the blood 
brain barrier.  Under severe hypertension the infracted area can go 
for haemorrhagic transformation. 
c. Temperature 
A two fold increase in the relative risk for poor outcome in 
stroke is seen with every 1oc rise of temperature.  This effect may 
be due to excitotoxic neurotransmitters. 
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COMPLICATIONS 
The most important local complication of cerebral infarction 
is the development of cerebral oedema, which impairs, possibly only 
temporarily, local blood flow and neuronal function over a wider 
area than just the infarct and, if extensive, causes transtentorial 
herniation.  There are a number of general complications of acute 
paralysis which include bronchopneumonia, particularly if 
consciousness or swallowing are impaired; venous 
thromboembolism; pressure sore and septicaemia; urinary 
infection, particularly if catheterization is necessary, and 
eventually uraemia; contractures in spastic limbs; frozen shoulder; 
cardiac rhythm disturbances; and mood disorder (Table).  Death in 
the first week is almost always due to the infarct itself and the 
effects of cerebral oedema, but later it is more often due to one of 
the general complications, particularly pneumonia. 
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Table 
General complications of stroke 
Respiratory Pneumonia 
Inhalation 
Pulmonary embolism 
Cardiovascular Myocardial infarction 
Cardiac failure 
Cardiac arrhythmia 
Neurogenic pulmonary oedema 
Infections Pneumonia 
Urinary track infection 
Skin 
Septicaemia 
Metabolic Vomiting 
Dehydration 
Electrolyte imbalance 
Hyperglycaemia 
Renal failure 
Mechanical Spasticity 
Contractures 
Malalignments/subluxation/frozen shoulder 
Falls and fractures 
Osteoporosis 
Ankle swelling 
Peripheral nerve pressure palsies 
Others Pressure sores 
Depression, anxiety, apathy 
Epileptic seizures 
Deep venous thrombosis 
Acute gastric ulceration 
Incontinence of urine/faeces 
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Course and Prognosis 
When the patient is seen early in the course of cerebral 
thrombosis, it is difficult to give an accurate prognosis.  No rules 
have yet been formulated that allow one to predict the course with 
confidence.  A mildparalysis today may become a disastrous 
hemiplegia tomorrow, or the patient’s condition may worsen only 
temporarily for a day or two.  In basilar artery occlusion, dizziness 
and dysphasia may progress in a few days to total paralysis and 
deep coma.   
The progression of the stroke is mostly often due to 
increasing stenosis of the involved artery by mural thrombus.  In 
some instances, extension of the thrombus along the vessel may 
block side branches and hinder anastomotic flow.  Embolic particles 
from the site of an incompletely thrombosed artery (artery-to-artery 
embolism) may precipitate an abrupt change.  Sometimes a 
completely thrombosed artery or an artery whose lumen is 
narrowed by a dissecting aneurysm can be the source of an embolus 
to more distal branches after a period of several days. 
Several other circumstances influence the immediate 
prognosis in cerebral thrombosis.  In the case of very large infarcts, 
swelling of the infracted tissue may occur, followed by displacement 
of central structures, tentorial herniation, and death of the patient 
after several days.  Smaller infarcts of the inferior surface of the 
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cerebellum may cause a fatal foramen magnum herniation.  Milder 
degrees of swelling and increased intracranial pressure may cause 
apparent progression for 2 to 3 days but do not prove fatal.  In 
extensive basilar infarction associated with deep coma, the 
mortality rate approaches 40 percent.  If coma or stupor is present 
from the beginning, survival is largely determined by the success in 
keeping the airway clear, controlling brain edema, preventing 
aspiration pneumonia, and maintaining fluid and electrolyte 
balance.  Respiratory and urinary infections are constant dangers: 
once they begin, there is usually a rapid decline in the patient’s 
condition as body temperature rises.  With smaller thrombotic 
infarcts, the mortality is 3 to 6 percent. 
Characteristically, the paralyzed muscles are flaccid in the 
first days or weeks following a stroke; the tendon reflexes are 
usually unchanged but may be slightly increased or decreased.  
Gradually spasticity develops, and the tendon reflexes become 
brisker.  The arm tends to assume a flexed adducted posture, and 
the leg an extended one.   
Function is rarely if ever restored after the slow evolution of 
spasticity.  Conversely, the early development of spasticity in the 
arm or the early appearance of a grasp reflex may presage a 
favourable outcome.  Bowel and bladder control usually returns; 
sphincteric disorders persist in only a few cases.  Often the 
hemiplegic limbs are at first tender and ache on manipulation.  
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Nevertheless, physiotherapy should be initiated early in order to 
prevent pscudocontracture of muscles and periarthritis at the 
shoulder, elbow, wrist, knuckles, knee, and ankle.   
Recurrent convulsive (epileptic) seizures are relatively 
uncommon sequelae of thrombotic strokes in comparison to embolic 
cortical infarcts, which are followed by recurrent focal or 
generalized seizures in more than 20 percent of patients. 
Many patients complain of fatigability and are depressed, 
possibly more so after strokes that involve the left frontal lobe 
(Starkstein et al.).  The explanation of these symptoms is 
uncertain; some are expressions of a reactive depression.  Only a 
few patients develop serious behaviour problems or are psychotic 
after a stroke, but paranoid trends, ill temper, stubbornness, and 
peevishness are common. 
Finally, in regard to prognosis, it must be mentioned that 
having had one thrombotic stroke, the patient is at risk in the 
ensuing months and year of having a stroke at the same or another 
site, especially if there is hypertension or diabetes mellitus.  When 
multiple infarcts occur over a period of months or years, a dementia 
may develop, in addition to focal cerebral deficits.  As a group these 
cases are referred to as multi-infarct dementia.  In some of these 
cases, the major lesions involve the white matter with relative 
sparing of the cortex and basal ganglia.  This type of lesion is often 
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referred to as a Binswanger’s subcortical encephalopathy, which is 
equated with multiple white matter infarcts and lacunes.  The part 
of the white matter that are destroyed have been shown to lie in 
the border zones between the penetrating cortical and basal 
ganglionic arteries. 
TREATMENT 
Medical treatment has a greater role to play than vascular 
surgery to alter the immediate outcome after cerebral infarction.  
In theory the reduction of cerebral oedema by mannitol, glycerol 
should be useful, but with regard to dexamethasone there have 
been no adequate clinical trials.  Thrombolysis causes intracerebral 
haemorrhage and this risk may not be out weighed by the potential 
benefit, if any.  Aspirin is currently being used.  Heparin has been 
recommended for stroke-in-evolution, although there have been no 
convincing trails and, since some cases may be due to haemorrhage 
into infarcted brain, this treatment is not to be recommended.  It is 
important to remember that there are many other reasons for 
stroke patients to deteriorate and some are potentially reversible. 
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Table 
Causes of neurological deterioration after stroke 
Local Extension of thrombus 
Recurrent embolism 
Recurrent haemorrhage 
Haemorrhagic transformation of the infarct 
Cerebral oedema 
Brain shift and herniation 
Hydrocephalus 
Epileptic seizures 
General  Hypoxia (pneumonia, pulmonary embolism, 
cardiac failure 
Hypotension (cardiac failure, cardiac arrhythmia, 
Septicaemia, pulmonary embolism, dehydration, 
Pneumonia, drugs, bleeding or perforated peptic 
ulcer) 
Infection (chest, urine, septicaemia) 
Dehydration 
Hyper-or hypoglycaemia 
Sedatives/hypnotics  
 
The complications of cerebral infarction are often preventable 
and treatable.  Chest physiotherapy and care of the airway, 
particularly in unconscious patients and those with difficulty in 
swallowing, will reduce the risk of pneumonia which, if it occurs, 
can be treated with antibiotics.  Occasionally intubation and 
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tracheostomy are needed in patients who cannot protect their 
airway due to impaired brain-stem reflexes, but who are otherwise 
expected to have a reasonably good prognosis.  Nasogastric tube 
feeding is used for adequate hydration and electrolyte balance in 
patients who cannot swallow, and later for feeding if necessary.  
Good nursing should prevent pressure sores.  Early physiotherapy 
will reduce the risk of contractures, pain, and stiffness in 
hemiplegic limbs and leads naturally on to active physical 
rehabilitation.  Urinary catheterization is often avoidable in males 
for whom an appliance is a better alternative, but in females it may 
be necessary so that the skin can be kept dry to reduce the chance 
of pressure sores.  Cardiac arrhythmias should be treated on their 
merits, but are not normally a problem.  Since cerebral infarcts can 
become haemorrhagic, it is uncertain whether deep venous 
thrombosis in the legs and pulmonary embolism should be 
prevented, or even treated, with antithrombotic drugs, but the 
benefit of high –does heparin followed by oral anticoagulation for 
major pulmonary embolism probably outweighs the risks.  
Epilepsy, if it occurs, should be treated in the usual way. 
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MATERIALS AND METHODS 
Setting 
The work was carried out in the medical wards of 
Government General Hospital, Chennai affiliated to Madras 
Medical College, Chennai.  
Study design 
Cross Sectional, analytical hospital based study. 
Period of study   
The study was carried out from November  2006 to May 2007. 
Ethical Approval  
The work was carried out after approval from ethical 
committee of Government General Hospital, Chennai (copy 
enclosed).  
Sample size 
 Study group (Stroke cases)   : 102  
 Control group     : 40 
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Methodology 
Study Group 
Government General Hospital is a tertiary care institute and 
referral centre for patients from all over South India. 
The stroke patients admitted within the above period and 
who satisfied the set criteria were included.  The number of 
patients in the present study group was 102. 
INCLUSION CRITERIA 
1. Patients with stroke as defined by WHO criteria 
Rapidly developing clinical signs of focal or global (coma) 
neurological deficit lasting more than 24 hrs or leading to death 
with no apparent cause other than vascular origin. 
2. All patients who presented within 48 hours of onset of stroke 
and who gave informed consent to participate in the study 
were included. 
EXCLUSION CRITERIA 
1. Patients with Sub arachnoid haemorrhage, extradural 
haemorrhage subdural haemorrhage and intra cerebral 
haemorrhage were excluded by CT. 
2. Patients with previous history of TIA/RIND.  
3. Patients with gout. 
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4. Patients who were alcoholics. 
5. Patients taking drugs causing hyperuricaemia.  
eg. With the following drugs like 
o Loop diuretics 
o Anticancer drugs (Cisplatin, cyclosporine, 
cyclophosphamide) 
o ATT (Pyrazinamide, Ethambutol) 
o Aspirin, Pentamidine, Theophylline, ketoconazole,  
o Levodopa, isotretinoin. 
6. Patients with previous history of coronary vascular events  
7. Kidney disease  
8. Patient on medication to reduce oxidant levels 
9. Hypothyroidism  
10. Inflammatory diseases 
11. Steroid therapy  
Control group 
People without stroke who satisfied the above exclusion 
criteria and matched for age, gender, diabetes, hypertension were 
taken as control.  The number of controls in the present study was 
40.  
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Data Collection  
 The socio demographic, clinical, laboratory parameters and 
outcome data were collected.  
 Socio demographic data included age of the patients, sex, 
area of residence, income, diet and time of hospitalisation after 
stroke.   
 Clinical data included recording of vital parameters, fundus 
examination, the type of stroke, conscious level of the patients 
assessed by the glasscow coma scale and complete neurological 
examination.  
 Laboratory parameters included complete blood count, renal 
function tests, fasting blood sugar and CT Scan brain.  
 The serum uric acid level was measured in the stroke 
patients and control by the uricase method.  
The test was done in the Biochemistry Lab at Government 
General Hospital, Chennai.  
Laboratory assessment of Uric acid (Uricase method) 
A reagent kit is available at the central biochemistry 
laboratory, Government General Hospital.  This reagent kit is for 
quantitative estimation of uric acid in serum or plasma. 
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Uricase 
Principle 
Uric acid + O2-2H2O          Allantoin + CO2 + H2O2 
2H2O2 + 4 Amino antipyrine + DHBS  → Chromogen + 4H2O 
Uric acid in serum is oxidized by uricase to allantoin and 
hydrogen peroxide.  Hydrogen peroxide thus generated is acted 
upon by peroxidase and oxidizes the chromogen (4 amino 
antipyrine + DHBS) to a red coloured compound which is read at 
520 nm (490-550 mm) or with a green filter.  The colour intensity at 
520 nm is proportional to the concentration of the uric acid in the 
sample. 
The reagent kit is provided with three solutions namely  
1. Uric acid (enzyme, chromogen) 
2. Uric acid (buffer) 
3. Uric acid (standard 5mg/dl) 
This reagent is for invitro diagnostic use. 
Preparation of working solution 
A working solution was prepared by dissolving the content of 
vial labeled I uric acid (enzyme) with the quantity of 2.  Uric acid 
(buffer).  The two solutions were mixed gently. 
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Specimen Collection 
Fresh clear serum with no hemolysis is the specimen of 
choice.  However, plasma collected from blood with heparin as an 
anti coagulant was used in the present study. 
Procedure 
The sample and working solution were brought to room 
temperature prior to use. 
25 μ1 of the sample is mixed with 1 ml of working reagent.  
The solution is incubated at 37oc for 5 min or 10 min at room 
temperature.  The wavelength of the solution and that of the blank 
reagent solution are compared at 520 nm or with green filter. 
Another procedure for 2.5 ml curette capacity is 
 Blank Standard Test 
Working 
reagent 
2.5 ml 2.5 ml 2.5 ml 
Standard - 0.05 ml - 
Sample -  0.05 ml 
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Absorbance of test 
                                         X 5 
Absorbance of Standard 
The mixed solution was incubated for 5 min at 37oc and read 
absorbance of the test and standard against reagent blank at 520 
nm or with green filter. 
Calculations 
 
Uric acid concentration mg/dl =  
 
To convert uric acid concentration from mg/dl to µmoles/L, 
the following equation was used 
µmoles/L = 59.5 X mg/dL 
µmoles/L = 0.0595 X mg/L 
Definitions  
Diabetes Mellitus :  People whose  fasting blood sugar more 
than 126 mg/dL and known patients with type 2 Diabetes mellitus 
on oral hypoglycaemic drugs or insulin therapy.   
Hypertension :  Patients with BP 140/90mm/Hg on 2 separate 
occasions, each on different days and known patients of 
hypertension on treatment.  
Serum uric acid level was measured in the stroke cases 
before they were treated with antiedema measures and aspirin. 
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Supportive care including physiotherapy was given. Neurologist 
opinion was obtained if needed. 
Outcome assessment  
 These patients were followed up for a period of 2 weeks in the 
hospital and the outcome in them assessed by Glassgow outcome 
scale28 at the end of 2 weeks.  
GLASGOW OUTCOME SCALE 
1. Indicates death 
2. Vegetative state (patient is unable to interact with 
environment) 
3. Severe disability (patients is unable to live independently but 
can follow commands) 
4. Moderate disability (patients is capable of living 
independently but unable to return to work or school). 
5. Mild or No disability Patient can return to work or school. 
Scale 4 & 5  -  Favourable outcome (good outcome) 
Scale 1,2 & 3  - Unfavourable outcome (poor outcome) 
The data were entered in microsoft excel software and 
analysed using SPSS 2007 statistically.  
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RESULTS 
 
GENDER 
In the 102 stroke patients, 66 were males and 36 females. 
The mean serum uric acid level in males (5.76 mg/dL) was higher 
than in females (5.47 mg/dL). No significant association was found 
between gender and uric acid level (P = 0.370) as shown in Table 
No. 1. 
 
TABLE 1 : SERUM URIC ACID LEVEL BETWEEN MALES & 
FEMALES IN THE STROKE CASES 
 
S. 
No. 
Gender  No.
Serum Uric Acid Level 
P value 
Mean SD C.I. 
1. Males 66 5.76 1.62 -0.347 
0.370 
2. Females 36 5.47 1.40 0.923 
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AGE 
 The age of stroke patients varied from 30 to 70 years. Mean 
age of the study group was 56.72 ± 1.89. The serum uric acid level 
was compared between age groups of > 50 and ≤ 50 years in the 
control and stroke cases.  
Control Group 
 In the control above 50 years had uric acid level more than 
people ≤ 50 years. But statistically it was not significant (P = 0.055) 
as shown in Table No. 2.  
 
TABLE  2 :  SERUM URIC ACID BETWEEN THE AGE GROUPS            
≤ 50 YEARS AND > 50 YEARS AMONG  CONTROL 
 
S. 
No. 
Age  No.
Serum Uric Acid Level 
P value
Mean SD C.I. 
1. ≤  50 years 19 4.050 0.7557 -0.3771 
0.055 
2. > 50 years 21 4.105 0.5862 0.4871 
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Stroke Cases 
Similarly within the stroke cases, uric acid level was 
compared between the age groups > 50 years and ≤ 50 years.  
In the stroke patients > 50 years had mean uric acid level of 
5.788 mg/dL while patients ≤  50 years had mean serum uric acid 
level 5.238 mg/dL. Statistical no association seen (P = 0.125), as 
shown in Table No. 3. 
 
TABLE 3 : SERUM URIC ACID BETWEEN AGE GROUPS ≤ 50 YEARS 
& > 50 YEARS AMONG STROKE CASES 
 
S. 
No.  
Age No.
Serum Uric Acid Level 
P value 
Mean SD C.I. 
1. ≤ 50 Years 34 5.238 1.578 -1.260 
0.127 
2. > 50 years 68 5.788 1.518 0.1588 
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SOCIO ECONOMIC STATUS 
 On the basis of Kuppusamy socio economic scale, it was found   
that 95 of the stroke cases belonged to low socio economic group 
while remaining 7 were of middle socio economic group. 
DIET 
 A detailed questionnaire was used to assess dietary habits of 
stroke subjects. 97 patients consumed non vegetarian diet while 4 
were pure vegetarians. But due to the low socio economic status of 
the majority, the quantity of non-vegetarian food consumed per 
week was considerably low.  
RESIDENCE 
¾ 54 patients were from rural areas. 
¾ 34 patients resided in semiurban areas 
¾ The remaining 14 patients were from urban areas.  
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URIC ACID LEVEL AND STROKE 
 The study group consisted of 102 stroke patients. The mean 
serum uric acid level in the stroke cases was 5.66 mg/dL with range 
4.12  to 7.2 mg/dL.  The control group had 40 members. The mean 
serum uric acid level in the control group was 4.08 mg/dL with 
range 3.41 to 4.75 mg/dL.   
The serum uric acid level of the stroke cases was compared 
with control group. The stroke cases had increased uric acid level 
than control with statistically significant association (P < 0.001) as 
shown in Table No. 4. 
TABLE NO. 4  : SERUM URIC ACID LEVEL BETWEEN STROKE 
CASES AND CONTROLS 
S. 
No. 
Group No. 
Serum Uric Acid Level 
P value
Mean SD C.I. 
1. Stroke Cases  102 5.66 1.54 -1.214 
0.000 
2. Control  40 4.08 0.67 -1.949 
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RISK FACTORS 
(i) Diabetes 
 In the study group 33 patients had diabetes and in the 
control group 11 were diabetics. The serum uric acid level was 
compared between them.  
Diabetics with stroke had elevated uric acid than diabetics 
without stroke (P < 0.001). Statistical association was present as 
shown in Table No. 5. 
 
TABLE  5 :  SERUM URIC ACID AMONG DIABETIC STROKE CASES 
AND CONTROL  
 
S. 
No. 
Group No. 
Serum Uric Acid Level 
P value
Mean SD C.I. 
1. Stroke Cases 33 5.50 1.59 -0.353 
0.009 
2. Control  11 4.15 0.63 -2.350 
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 Similarly serum uric acid level in diabetics and non diabetics 
within the stroke cases were compared. The mean uric acid level in 
diabetics with stroke was 5.74 mg/dL while that of non diabetic 
stroke patients were 5.49 mg/dL. There is no statistical significance 
between them (P = 0.467) as shown in Table No. 6. 
 
TABLE 6 : SERUM URIC ACID AMONG DIABETIC AND NON 
DIABETIC STROKE CASES 
 
S. 
No. 
Risk Factor  No.
Serum Uric Acid Level P 
value Mean SD C.I. 
1. Diabetics  33 5.74 1.526 0.889 
0.467 
2. Non Diabetics 69 5.4970 1.588 0.410 
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DIABETES AND OUTCOME  
 The outcome was compared between the diabetics and non 
diabetics in the stroke patients.  
 In the diabetic poor outcome (54.5%) was more common than 
good outcome (45.5%) but not statistically significant (P = 0.057) as 
shown in Table No. 7. 
TABLE 7 : OUTCOME IN DIABETIC AND NONDIABETIC STROKE 
CASES  
Cases 
Outcome 
Total 
Good Poor 
Diabetes  15 
(45.5%) 
18 
(54.5%) 
33 
(32.4%) 
Non Diabetics  45 
(65.2%) 
24 
(34.8%) 
69 
(67.6%) 
Total 42 
(41.2%) 
60 
(58.8%) 
102 
(100%) 
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HYPERTENSION 
 Among the stroke cases, 54 were hypertensive, while in the 
control 12 were hypertensive. The serum uric acid level was 
compared between them.   
 The hypertensive in control had mean uric acid of 4.06 mg/dL 
while the hypertensive in cases had mean uric acid of 5.71 mg/dL. 
There is significant association between stroke patients with 
hypertension and elevated uric acid (P = 0.001) as shown in Table 
No.8.  
TABLE 8 : SERUM URIC ACID AMONG HYPERTENSIVE STROKE 
CASES & CONTROL 
 
S. 
No. 
Group No. 
Serum Uric Acid Level 
P value 
Mean SD C.I. 
1. Cases 54 5.71 1.53 -0.751 
0.001 
2. Control 12 4.06 0.59 -2.551 
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When the serum uric acid level was compared between the 
hypertensive and non hypertensive within the stroke cases there 
was no significant association (P = 0.728) as shown in Table No.9.  
 
TABLE 9  :  SERUM URIC ACID AMONG HYPERTENSIVES AND 
NON HYPERTENSIVES WITHIN STROKE CASES  
 
S. 
No. 
Risk Factor  No. 
Serum Uric Acid Level 
P value
Mean SD C.I. 
1. Hypertensive  54 5.71 1.53 -0.503  
0.728 2. Non 
Hypertensive  
48 5.60 1.57 0.717 
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SMOKING 
 In the stroke cases 44 were smokers. Their uric acid level was 
compared with that of the non smokers among the stroke cases.   
There was no significant association (P = 0.879) as shown in Table 
No.10. 
 
TABLE 10 :  SERUM URIC ACID AMONG SMOKERS AND NON 
SMOKERS IN THE STROKE CASES  
 
S. 
No. 
Risk factor  No. 
Serum Uric Acid Level 
P value 
Mean SD C.I. 
1. Smokers  44 5.63 1.58 -0.633  
0.879 
2. Nonsmokers  58 5.68 1.52 0.568 
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STROKE OUTCOME AND URIC ACID 
 Of the 102 cases, 91 had middle cereberal artery territory 
infarct, while 11 had posterior circulation stroke. The outcome was 
analysed in the stroke patients using glasscow outcome scale. 60 of 
them had good outcome while 42 had poor outcome as shown in the 
Figure - 2.  
Fig. 2   
OUTCOME SCALE IN THE STROKE PATIENTS  
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  The serum uric acid level was compared between stroke cases 
with good outcome and poor outcome. 
 Mean serum uric acid in the stroke patients with poor 
outcome (6.41 mg/dL) was higher than that in the stroke patients 
with good outcome (5.13 mg/dL).  
 There is statistical association (P value < 0.001) between 
increased uric acid level and poor outcome as shown in Table 
No.11.  
 
TABLE 11   :  SERUM URIC ACID AMONG STROKE CASES IN 
RELATION TO OUTCOME  
S. 
No. 
Stroke Cases No. Mean SD C.I. P value 
1. Good outcome 60 5.13 1.45 0.716 
0.001 
2. Poor outcome  42 6.41 1.37 1.845 
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 The stroke patients without selected risk factors 
(hypertension, diabetes, smoking) were 38 in the study. Among 
them, the uric acid level was compared between those with good 
outcome and poor outcome.   
Mean serum uric acid in the stroke patients without risk 
factors and poor outcome (4.92 mg/dL) was higher than those with 
good outcome (6.32 mg/dL).  
 There is a significant association between elevated uric acid 
level and poor outcome in stroke patients without risk factors  
(P < 0.001) shown in Table No.12. 
TABLE 12 : SERUM URIC ACID IN STROKE PATIENTS WITHOUT 
RISK FACTORS WITH OUTCOME 
 
S. 
No. 
Stroke 
Cases 
No. 
Serum Uric Acid Level 
P value 
Mean SD C.I. 
1. Good 
outcome 
15 4.92 1.61 4.03 to 
5.8 
< 0.001 
2. Poor 
outcome  
23 6.32 0.69 5.8 to 
6.8 
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DISCUSSION 
 Uric acid which is an end product of purine metabolism has 
long been considered only in the pathogenesis of gout and uric acid 
stones. Its anti-oxidant functions and its various role in the 
pathogenesis of hypertension, cardiovascular and cerebrovascular 
events are been considered of late. Various studies conducted 
during recent years on serum uric acid levels in vascular events 
have proven its prognostic significance.  
 Uric acid is also been considered as a marker for 
atherosclerosis. But the exact pathogenesis and whether it is the 
cause or effect of atherosclerosis remains to be elucidated.  
Uric Acid and Gender  
 The serum uric acid level was compared between male and 
female stroke patients. Though it was increased in males, 
statistical association between gender and uric acid was not 
present. But in a study by Chamorro et al.29 serum uric acid levels 
were found to be  higher in males. 
 63
Age Group 
 In our study, most of the patients were in the age group of 50 
years and above i.e. 76% of patients.  
 Stroke occurs predominantly in the middle and late years of 
life30. When serum uric acid level was compared between age 
groups of ≤ 50 years and > 50 years in control and cases, there was 
no significant association.  
 Age group of the patients has been found to have no 
correlation with serum uric acid levels in the present study. 
 In a study by Milionis et al.31 elevated uric acid was 
associated with increased risk of ischemic stroke in individuals 
above 70 years.  Since in the present study, patients older than 70 
years were not present, this correlation is not possible.  
Uric Acid Level among Control & Stroke Patients  
 Uric acid levels were found to be significantly higher among 
patients with stroke than the control in this study. A study by 
Hozawa A. Folsom et al.32 also showed increased uric acid levels in 
patients with ischemic stroke.  
 Longo Mbenza, et al.33 in a study among African patients 
found that uric acid levels were elevated among stroke patients. In 
a study by Iribarreen, Folsom and Eckfeldt et al., 34 they tried to 
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find the correlation between uric acid levels and asymptomatic 
carotid atherosclerosis. They found a positive correlation between 
the two and that uric acid level can be used to predict future 
cerebrovascular events.  
Uric Acid and Diabetics 
 In the present study diabetic patients who developed stroke 
had higher uric acid level than the diabetics in the control group 
with significant association.  
 Among the stroke patients no significant difference in uric 
acid levels was found between diabetics and non diabetics.  
 Lehto et al.35 studied uric acid levels in diabetics patients 
prospectively and showed that it was more elevated in the diabetics 
who developed stroke.  
Diabetics and Outcome 
 Among the stroke patients, outcome in diabetic and non 
diabetic was analysed, diabetics had higher percentage of poor 
outcome (54.5%) than good outcome (45.5%), but statistically no 
significant association (P = 0.057) was seen. A study by Wang, Lim 
et al.36 showed that hyperglycemia increases stroke mortality. In 
yet another study by Yoon, et al.37, they found high blood glucose is 
associated with poor outcome after ischemic stroke. In the present 
study only 33% of stroke patients were diabetics. So this correlation 
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was probably not possible. We may need a large multicentered 
study.  
Hypertension and uric acid  
 Hypertensive patients who developed stroke had increased 
uric acid level than the hypertensive in the control group with 
statistical significant association (P < 0.001). Among the stroke 
patients, no significant difference in uric acid level was found 
between the hypertensive and non hypertensives.   
 In a study by Verdecchia P and Schillaci et al.,38  it was 
proven that there is a definite relation between serum uric acid and 
essential hypertension.  
 Theodore R Fields et al.,38 in his study on uric acid and 
cardiovascular disease discussed pathogenic role of uric acid in 
hypertension - ‘Chicken and Egg’ theory ie., whether uric acid is the 
cause or effect of hypertension. In his study, he included coronary 
artery diseases also and found that uric acid has no etiological role 
in hypertension. His conclusion was that elevated uric acid is 
secondary to the systemic hypertension.  
 Elevated serum uric acid in hypertensives can be associated 
with ischemic stroke. This has been showed in a study by 
Franeesea Viazzi et al.,39 who found that cerebrovascular events 
was higher in hypertensives with increased uric acid level.  
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Smoking 
 Smoking was not found to be associated with elevated uric 
acid levels among patients with stroke in this study.  
 Angel Chamorro et al.34 in his study has proven that uric acid 
levels are independent of smoking. However, associated 
atherosclerosis can elevate the uric acid levels falsely giving an 
impression that smokers have elevated uric acid levels. 
Uric Acid and outcome in stroke patients  
 Elevated uric acid was found to be significantly associated  
with poor outcome among the stroke patients in the present study.  
 To eliminate the potential bias created by risk factors 
(diabetes, hypertension, smoking), the uric acid level was analysed 
among stroke patients without these selected risk factors and 
compared with outcome.  It was found that uric acid was still an 
independent indicator of poor outcome.  
 According to Weir et al.40 serum uric acid can be an 
independent predictor of poor outcome and future vascular events 
after acute stroke.  
 In his study serum uric acid concentrations was measured in 
an unselected cohort study of stroke survivors and was followed up. 
Uric acid was associated with a statistically significant three fold 
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increase in relative risk of death, even after adjustment for other 
conventional risk factors.  
 Uric acid being an anti oxidant, it is increased as a 
compensatory mechanism to protect the ischemic tissues of the 
brain from free radical injury41. Present observation concurs with 
the above statement.    
 Recent evidence suggests that acute ischemic stroke results 
in generation of local oxidants that augment local injury and 
increase infarct size. Acute stroke is associated with a rapid 
decrease in serum antioxidants that recover slowly over subsequent 
weeks42. Though uric acid is considered an antioxidant, it being an 
aqueous antioxidant, it can become a pro-oxidant under certain 
circumstances, particularly if other antioxidants such as ascorbate 
are low43. Thus fall in ascorbrate (Vitamin C) levels with acute 
stroke could predispose the serum uric acid to take on pro-oxidant 
properties. Acute stroke cases with high uric acid and low acerbate 
levels had worst outcome in a study carried by Cherubini et al44.   
 However, it has been evident by experiments that uric acid is 
synthesised locally from infarcted tissues, particularly during 
reperfusion and its level in serum rises often in proportion to the 
size of the infarcted tissue, reperfusion status and the extent of the 
free radical injury.  
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 So elevated uric acid though not, an abnormality and only a 
response to physiological stress, and to some extent is a biochemical 
marker of oxidative stress. As definite correlation between 
oxidative stress and serum uric acid level was not made earlier, 
therapeutic intervention for elevated uric acid should not be 
undertaken.  However, it still can be used a surrogate biochemical 
marker for the oxidative stress in acute ischemic stroke. The 
elevated uric acid may indirectly reflect high amount of oxidative 
stress and therefore poor outcome in stroke patients.   
 To ascertain the above statement, large series of cases of 
stroke has to be studied along with other variables for oxidative 
stress and compared with uric acid.  
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SUMMARY 
PURPOSE  
 To estimate the level of serum uric acid in patients with 
acute ischemic stroke, to find out its association with diabetes and 
hypertension, to correlate with age and gender and to study its 
significance in the out come of the stroke patients.  
METHODS 
 A cross section study was designed after institutional ethical 
clearance to screen acute ischemic stroke patients admitted to the 
hospital within 48 hours of stroke who satisfied a rigid inclusion 
and exclusion criteria. Another 40 members with similar variables 
without stroke were taken as control. The serum uric acid level was 
measured by uricase method. The outcome in the stroke patients 
was analysed at the end of 2 weeks while in hospital. The data were 
entered in microsoft excel spread sheet and analysed statistically.  
Results 
 There were 102 stroke patients. Among them there were 66 
males and 36 females. Their age varied from 30 to 70 years and the 
mean age was 56.72 years. The uric acid level among the stroke 
cases varied from 4.12 to 7.2 mg/dL and the mean serum uric acid 
level was 5.66 mg/dL. It was elevated significantly than the control 
group (P< 0.001). Stroke patients with diabetics and hypertension 
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had elevated serum uric acid level than the counter parts in the 
control and the difference was significant statistically (P<0.001). 
Those stroke cases with elevated uric acid had poor outcome and 
statistically was significant (P < 0.001). 
Conclusion 
 Serum uric acid level was increased in stroke patients and 
was independent of age and gender. Uric acid level among stroke 
cases was independent of their diabetic and hypertensive status. 
All the stroke cases who had poor outcome were found to have 
elevated uric acid level which may be a response to oxidative stress 
and hence it can be considered as biochemical marker in stroke 
patients.  
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CONCLUSION 
1. Serum Uric Acid was higher in stroke patients than the 
control group and it was significant (P < 0.001).  
2. Age and gender did not influence the serum uric acid level 
in the stroke patients.  
3. Uric acid level was elevated in stroke cases with diabetics 
and hypertension and it was significant (P<0.001). 
4. Among stroke cases, uric acid level was independent of 
diabetes and hypertension.  
5. Stroke patients with elevated uric acid had poor outcome 
and it was significant (P<0.001). 
6. Uric acid has been considered as a surrogate biochemical 
markers of oxidative stress in acute ischemic stroke. 
Elevated uric acid among stroke patients concurred with 
previous publication.  
 
 
 
 
